论文信息 - Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial. - 字舞流文

Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.

G. Pond | M. Michaelson | G. Sonpavde | S. Clarke | I. Chen | J. Vardy | J. Paolini | Matthew R. Smith | E. C. Maneval | M. Lechuga | Shaw-Ling Wang